Introduction {#s1}
============

About 50 epidemiological studies of ovarian cancer have collected information on the relevance of women\'s adult height and weight to their subsequent risk of ovarian cancer [@pmed.1001200-Newhouse1]--[@pmed.1001200-Schouten2]. Only about half these studies have published their results on the association between body size and ovarian cancer risk, and the findings are inconsistent [@pmed.1001200-Purdie1],[@pmed.1001200-Kuper1],[@pmed.1001200-Rodriguez1],[@pmed.1001200-Anderson1],[@pmed.1001200-Riman1],[@pmed.1001200-Greer1]--[@pmed.1001200-Rossing1],[@pmed.1001200-Leitzmann1]--[@pmed.1001200-Schouten2]. An international collaboration was set up to bring together, re-analyse, and publish the available epidemiological evidence on the association between hormonal, anthropometric, and other factors and ovarian cancer risk [@pmed.1001200-Collaborative1]. This report describes the relationship between ovarian cancer risk and adult height, weight, and body mass index, and examines the consistency of the findings across study designs, across subgroups of women, and by tumour histology. Data from studies that had and had not published on the association with body size are included here, as this helps avoid unduly selective emphasis on particular studies, or just on published results.

Methods {#s2}
=======

Identification of Studies and Collection of Data {#s2a}
------------------------------------------------

Our collaboration began in 1998, and since then potentially eligible epidemiological studies have been sought regularly, by searches of review articles and through computer-aided literature searches in MEDLINE, EMBASE, and PubMed using combinations of the search terms "ovarian cancer", "ovary cancer", "height", "body mass index", "body size", "anthropometr\*". To be eligible for these analyses, studies needed to have collected individual data on women\'s reproductive history, use of hormonal therapies, height, weight, and/or body mass index, studied at least 200 women with ovarian cancer, and published their findings before 1 January 2009. (Before 2006, studies with fewer than 200 cases of ovarian cancer had been eligible, and so there are fewer cases in some studies.) Studies that had collected relevant data but had not published on ovarian cancer and body size were sought by correspondence with colleagues, by discussions at collaborators meetings (in 2000, 2005, and 2011), and by electronic searches using the additional terms "cohort", "prospective", "women", and "cancer risk".

We identified 51 eligible studies and invited principal investigators from each study to participate in the collaboration. Investigators from just one eligible study [@pmed.1001200-Hoyo1] did not respond to any of our enquiries, and investigators from another study [@pmed.1001200-Mills1] wrote to say that they were unable to participate. Two other studies [@pmed.1001200-Peterson1],[@pmed.1001200-Olsen1] have contributed to the collaboration, but their data were not available for these analyses. Thus, data from 47 of the 51 eligible studies identified are analysed here. The implications of this are discussed later.

"Cases" are women with malignant epithelial or non-epithelial ovarian cancer and "controls" are women without ovarian cancer who had not undergone bilateral oophorectomy. Information sought from principal investigators about every control and about every case included their age, ethnic group, education, height, weight and/or body mass index, age at menarche, reproductive history, use of hormonal contraceptives, use of menopausal hormonal therapy, hysterectomy, family history of ovarian or breast cancer, and consumption of alcohol and tobacco. The information sought on these factors was for the time preceding the onset of disease for cases and for an equivalent time for controls. So that similar analytical methods could be used across studies, cohort studies were incorporated using a nested case--control design, in which up to four controls were selected at random and matched at follow-up by age of the case at entry into the cohort, age at cancer diagnosis, and, where appropriate, broad geographical region. In one cohort study "cases" were women with fatal ovarian cancer [@pmed.1001200-Rodriguez1], whereas in the other studies "cases" were women with incident disease.

Principal investigators of 47 epidemiological studies included in the analyses [@pmed.1001200-Newhouse1]--[@pmed.1001200-Lahmann1] provided individual information on adult height, weight, and/or body mass index for cases and controls ([Table 1](#pmed-1001200-t001){ref-type="table"}). Body mass index was calculated as weight (in kilograms) divided by height (in metres) squared. In one case--control study [@pmed.1001200-Newhouse1], information was available for height but not for weight or body mass index, and in seven small case--control studies [@pmed.1001200-Casagrande1]--[@pmed.1001200-Byers1],[@pmed.1001200-Wu1],[@pmed.1001200-Whittemore1],[@pmed.1001200-Hartge1], information for body mass index, but not for weight or height, was available (these seven studies had been conducted more than 30 y ago, and original data on weight and height could no longer be retrieved). Information provided by principal investigators on a woman\'s adult weight and height before the onset of disease was used in these analyses. If more than one value for either variable was provided for a particular study, the values used in the analyses were those that best represented the woman\'s height and weight at that time. For retrospective case--control studies, this was usually women\'s height and weight some 1--5 y before the diagnosis of ovarian cancer, and at an equivalent time for controls. For prospective studies, principal investigators generally provided information on women\'s height and weight recorded at the time they were recruited into the cohort. A small number of women in some of the cohorts may have already lost weight because of an as-yet-undiagnosed ovarian cancer, and so sensitivity analyses were done excluding the first 4 y of follow-up in the prospective studies. All data contributed by principal investigators were checked and collated centrally so that analyses could use definitions as similar as possible across studies. Apparent inconsistencies in the data were rectified, where possible, by correspondence with the investigators. After the records had been checked and corrected, investigators were sent summary tables and listings of the variables to be used in analyses for final confirmation.

10.1371/journal.pmed.1001200.t001

###### Details of studies and women included.

![](pmed.1001200.t001){#pmed-1001200-t001-1}

  Study (Country) \[Reference\]                                              Number of Cases/Controls   Median Year of Diagnosis (Cases)   Median Year of Birth (Cases)   Mean Age (Cases)   Mean Height (cm)/Mean Body Mass Index (kg/m^2^) (Controls)
  ------------------------------------------------------------------------- -------------------------- ---------------------------------- ------------------------------ ------------------ ------------------------------------------------------------
  **Prospective studies (** ***n*** ** = 17)**                                                                                                                                              
  Oxford/FPA (UK) [@pmed.1001200-Vessey1]                                             49/196                          1988                             1937                     48.1                                 161.5/22.9
  BCDDP (US) [@pmed.1001200-Lacey1]                                                 353/1,381                         1989                             1923                     65.3                                 162.0/25.3
  Nurses\' Health Study (US) [@pmed.1001200-Kotsopoulos1]                           677/2,710                         1991                             1930                     58.7                                 163.7/25.3
  Iowa Women\'s Health [@pmed.1001200-Anderson1]                                     179/716                          1991                             1924                     68.0                                 162.4/23.8
  Radiation technologists (US) [@pmed.1001200-Doody1]                                 44/176                          1992                             1945                     47.5                                 164.5/23.6
  Netherlands Cohort (Netherlands) [@pmed.1001200-Schouten1]                        248/1,739                         1992                             1923                     67.8                                 165.2/25.1
  CNBSS (Canada) [@pmed.1001200-Silvera1]                                           481/1,922                         1993                             1932                     59.1                                 161.7/25.1
  Norwegian Counties [@pmed.1001200-GraffIversen1]                                   130/520                          1993                             1937                     55.1                                 162.8/25.8
  CPS-II Mortality (US) [@pmed.1001200-Rodriguez1]                                 2,697/1,1367                       1994                             1923                     70.3                                 162.9/24.8
  Swedish mammography [@pmed.1001200-Larsson1]                                      289/1,143                         1996                             1931                     64.1                                 163.9/25.2
  CPS-II Nutrition (US) [@pmed.1001200-Patel1]                                      355/1,419                         1997                             1929                     67.8                                 163.8/25.6
  WLH (Norway/Sweden) [@pmed.1001200-Kumle1]                                         105/417                          1998                             1947                     48.7                                 165.9/23.0
  NIH-AARP (US) [@pmed.1001200-Leitzmann1]                                          751/3,009                         1999                             1932                     65.9                                 163.1/26.7
  EPIC (eight European countries) [@pmed.1001200-Lahmann1]                          444/1,788                         2000                             1935                     63.7                                 161.3/25.6
  NOWAC (Norway) [@pmed.1001200-Bakken1]                                             102/414                          2000                             1940                     59.8                                 164.8/25.0
  PLCO (US) [@pmed.1001200-Buys1]                                                    201/805                          2001                             1933                     68.1                                 163.1/26.9
  Million Women Study (UK) [@pmed.1001200-Reeves1]                                 3,753/15,009                       2002                             1941                     61.0                                 162.0/25.7
  All prospective studies                                                         10,858/44,731                       1999                             1934                     64.1                                 162.7/25.3
  **Case--control studies with population controls (** ***n*** ** = 17)**                                                                                                                   
  Casagrande/Pike (US) [@pmed.1001200-Casagrande1]                                   150/150                          1974                             1932                     40.2                                  NA/22.9
  Weiss (US) [@pmed.1001200-Farrow1]                                                298/1,135                         1977                             1921                     55.1                                 162.2/23.3
  CASH (US) [@pmed.1001200-The1]                                                    575/4,238                         1981                             1937                     41.9                                 164.123.0
  Whittemore (US) [@pmed.1001200-Whittemore1]                                        232/679                          1984                             1933                     50.5                                  NA/24.0
  Shu/Brinton (China) [@pmed.1001200-Shu1]                                           228/229                          1985                             1933                     48.4                                 158.5/22.1
  Western New York (US) [@pmed.1001200-McCann2]                                      122/692                          1988                             1930                     58.4                                 162.9/25.6
  Risch (Canada) [@pmed.1001200-Risch1]                                              450/564                          1991                             1934                     56.7                                 162.9/24.5
  Green/Purdie (Australia) [@pmed.1001200-Purdie1]                                   784/853                          1992                             1935                     55.1                                 162.0/24.2
  Mosgaard (Denmark) [@pmed.1001200-Mosgaard1]                                      905/1,093                         1992                             1943                     45.9                                 166.5/23.7
  Cramer (US) [@pmed.1001200-Kuper1]                                                 563/525                          1993                             1942                     51.1                                 162.9/25.3
  Riman (Sweden) [@pmed.1001200-Riman1]                                             807/3,875                         1994                             1932                     61.5                                 163.8/25.3
  German OCS [@pmed.1001200-Royer1]                                                  281/531                          1995                             1937                     55.2                                 163.9/22.1
  Pike/Wu (US) [@pmed.1001200-Pike1]                                                 477/660                          1995                             1939                     55.5                                 163.6/23.4
  Goodman/Wu (US) [@pmed.1001200-Goodman1]                                           719/892                          1996                             1942                     55.0                                 159.0/24.5
  NISOC study (Israel) [@pmed.1001200-Modan1]                                      1,237/2,103                        1996                             1939                     56.0                                 161.0/25.0
  OVCARE (US) [@pmed.1001200-Rossing1]                                              376/1,637                         1996                             1950                     45.7                                 165.0/24.9
  SHARE (US) [@pmed.1001200-Greer1]                                                 767/1,364                         1996                             1943                     51.6                                 162.5/25.9
  All with population controls                                                     8,971/21,220                       1994                             1939                     52.7                                 163.2/24.3
  **Case--control studies with hospital controls (** ***n*** ** = 13)**                                                                                                                     
  Byers (US) [@pmed.1001200-Byers1]                                                  163/753                          1960                             1908                     52.3                                  NA/26.4
  Newhouse (UK) [@pmed.1001200-Newhouse1]                                            280/582                          1973                             1918                     54.1                                  160.7/NA
  McGowan (US) [@pmed.1001200-McGowan1]                                              182/192                          1975                             1923                     50.4                                  NA//23.3
  Paffenbarger (US) [@pmed.1001200-Wu1]                                              110/480                          1975                             1917                     55.6                                  NA/24.1
  Hildreth/Kelsey (US) [@pmed.1001200-Hildreth1]                                     62/1,047                         1978                             1918                     60.1                                  NA/24.9
  Hartge (US) [@pmed.1001200-Hartge1]                                                293/333                          1979                             1924                     54.3                                  NA/23.2
  Booth (UK) [@pmed.1001200-Booth1]                                                  286/489                          1980                             1927                     50.9                                 162.8/24.1
  Rosenberg (US) [@pmed.1001200-Rosenberg1]                                         952/3,808                         1983                             1935                     49.5                                 162.8/26.6
  Negri/Franceschi(Italy) [@pmed.1001200-Parazzini1]                                957/2,478                         1986                             1932                     53.1                                 160.9/23.8
  PEDS (US) [@pmed.1001200-McCann1]                                                 411/1,752                         1989                             1933                     54.5                                 162.5/25.5
  Tzonou/Tricopoulos (Greece) [@pmed.1001200-Tzonou1]                                319/396                          1990                             1929                     56.0                                 160.9/24.7
  Negri (Italy) [@pmed.1001200-Chiaffarino1]                                        1026/2,398                        1995                             1939                     54.9                                 161.1/25.3
  Zhejiang-Curtin (China) [@pmed.1001200-Zhang1]                                     287/652                          1999                             1952                     46.3                                 158.3/22.1
  All with hospital controls                                                       5,328/15,360                       1986                             1932                     52.7        
  **All 47 studies**                                                            **25,157/81,311**                   **1994**                         **1935**                 **57.6**                             **162.7/25.0**

NA, not available.

Information on the histological classification of the ovarian cancers was provided by principal investigators of all but seven [@pmed.1001200-Byers1],[@pmed.1001200-Tzonou1],[@pmed.1001200-Whittemore1],[@pmed.1001200-Parazzini1],[@pmed.1001200-Vessey1],[@pmed.1001200-Rodriguez1],[@pmed.1001200-Doody1] of the 47 participating studies and was used to categorize tumours centrally, based on the classification system of the *International Classification of Diseases for Oncology* [@pmed.1001200-World1]. Tumours were subdivided as epithelial or non-epithelial, and the epithelial tumours were further classified as clear cell, endometrioid, mucinous, serous, mixed, or other. Wherever possible the epithelial tumours were further subdivided into those that were of borderline malignancy or fully malignant.

Statistical Analysis and Presentation of Results {#s2b}
------------------------------------------------

The analytical methods were similar to those used previously [@pmed.1001200-Collaborative1]. Data from different studies were combined by means of the Mantel-Haenszel stratification technique, subdividing data into fine strata, each with a separate estimate of standard "observed minus expected" (*O−E*) numbers of women with ovarian cancer, together with their variances and covariances [@pmed.1001200-Peto1],[@pmed.1001200-Peto2]. Use of these simple stratified *O−E* values has the advantage of avoiding assumptions about the precise forms of any relations in the data. The stratified *O−E* values, together with their variances, were summed to yield both odds ratios (subsequently referred to as relative risks) and associated *p*-values. When only two groups were compared, relative risk estimates were obtained from the *O−E* value and its variance (var\[*O−E*\]) by the one-step method [@pmed.1001200-Peto1],[@pmed.1001200-Peto2], as were their standard errors and confidence intervals (CIs). (The exact formula was as follows: log relative risk = \[*O−E*\]/var\[*O−E*\]). When more than two groups were compared, variances were estimated for every group, by treating the relative risks as floating absolute risks [@pmed.1001200-Easton1]. This method does not alter relative risk estimates, but reduces the variances attributed to them (except for the baseline group, where the relative risk is defined as 1.0) and allows the relative risk estimates to be treated as approximately independent in tests of heterogeneity and trend. The group-specific variances were used to calculate group-specific CIs (g-s CIs). Use of this method enables valid comparisons between any two groups, even if neither is the baseline group. Any comparison between two relative risks must, therefore, take the variation in each group into account. Heterogeneity between relative risk estimates was assessed using chi-squared statistics.

To ensure that women in one study were compared directly only with similar women in the same study, all analyses were routinely stratified by study, by centre within study, by age (in 5-y age groups, with women aged over 90 y excluded), parity (0, 1+), use of oral contraceptives (no, for \<5 y, 5+ y), ever use of hormonal therapy for the menopause (yes, no), and menopausal status or hysterectomy (pre/perimenopausal, natural menopause before age 50, natural menopause after age 50, previous hysterectomy, other). Unknowns for each stratification variable were assigned to separate strata. Analyses in relation to height were also adjusted by body mass index, and analyses in relation to body mass index and to weight were also adjusted by height; results of sensitivity analyses to assess the effect of these mutual adjustments are presented. The effect on the main findings of other potential confounding factors (year of birth, ethnic group, education, family history of ovarian or breast cancer, age at menarche, menopausal status, alcohol use, and smoking) was examined by comparing results before and after stratification for each variable, in turn, and all simultaneously.

The relative risk of ovarian cancer per 5 cm increase in height and per 5 kg/m^2^ increase in body mass index was estimated by fitting a log-linear trend across categories of height (\<155, 155--, 160--, 165--, 170--, 175+ cm) and body mass index (\<20, 20--, 22.5--, 25--, 27.5--, 30--, 32.5--, 35+ kg/m^2^) using the median value within each category.

Results in the figures are presented by squares and lines, respectively, representing the relative risks and their corresponding 95% or 99% CIs or g-s CIs. The position of the square indicates the value of the relative risk, and its area is inversely proportional to the variance of the logarithm of the relative risk, thereby providing an indication of the amount of statistical information available for that particular estimate. When results from many studies or many subgroups are presented in the figures, 99% CIs/g-s CIs are given, since because of the multiple testing, *p*-values greater than 0.01 may well be due to chance. In the text and in figures summarizing the main results, 95% CIs are given.

In high-income countries the average height has increased by about 1 cm per decade [@pmed.1001200-Cole1], and the average body mass index has increased by about 1 unit per decade [@pmed.1001200-Prospective1]. To illustrate the public health consequences of the secular trend of increasing height and weight among women in such countries, we applied the relative risks obtained here per centimetre increase in height and per unit increase in body mass index to estimate how ovarian cancer rates would have changed per decade, had all other factors relevant for ovarian cancer remained constant. The PRISMA checklist is provided as [Text S1](#pmed.1001200.s001){ref-type="supplementary-material"}.

Results {#s3}
=======

Details of the women in the 47 participating studies are shown in [Table 1](#pmed-1001200-t001){ref-type="table"}. The studies are grouped by their design and, within each type of design, are ordered by the median year when the ovarian cancers were diagnosed. Altogether the 47 studies were conducted in 14 countries. The studies contributed a total of 25,157 women with ovarian cancer (cases) and 81,311 women without ovarian cancer (controls), with almost half the cases from Europe and half from North America. The cancers were diagnosed in 1994, on average, and the mean age at diagnosis was 57.6 (standard deviation, 12.5) y. The percentages aged \<35, 35--44, 45--54, 55--64, and 65 y or older at diagnosis were 5%, 10%, 22%, 32%, and 31%, respectively. Among controls the average height was 162.7 (standard deviation, 7.0) cm, and the average body mass index was 25.0 (standard deviation, 4.9) kg/m^2^.

Ovarian cancer risk increased significantly both with increasing height and with increasing body mass index (*p*\<0.001 for each). However, there was highly significant variation in the findings by study design (*p* ~heterogeneity~\<0.001 for each); this is illustrated in [Figure 1](#pmed-1001200-g001){ref-type="fig"}, which shows study-specific relative risks of ovarian cancer risk per 5 cm increase in height and per 5 kg/m^2^ increase in body mass index, grouped by study design. Studies contributing relatively small amounts of statistical information (where the reciprocal of var\[log relative risk\] is less than 30) are included in the "other" category for the relevant study design. The variation by study design is largely due to the qualitatively different results for case--control studies with hospital controls compared to results for case--control studies with population controls or for prospective studies. The possibility that some of the hospital controls were women with conditions affected by height and body mass index cannot be excluded, and so studies with hospital controls are excluded in subsequent analyses (see [Discussion](#s4){ref-type="sec"}).

![Relative risk of ovarian cancer in relation to height and body mass index by study.\
Relative risk^1^ (RR^1^) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, body mass index, duration of oral contraceptive use, and ever use of hormone therapy. Relative risk^2^ (RR^2^) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, height, duration of oral contraceptive use, and ever use of hormone therapy. SE, standard error.](pmed.1001200.g001){#pmed-1001200-g001}

Height {#s3a}
------

The taller women were, the greater was their risk of ovarian cancer ([Table 2](#pmed-1001200-t002){ref-type="table"}). The adjusted relative risk for ovarian cancer was 1.07 (95% CI, 1.05--1.09, *p*\<0.001) for every 5 cm increase in height. Analyses were stratified by study, age, parity, menopausal status, hysterectomy, oral contraceptive use, use of hormone therapy for the menopause, and body mass index. It can be seen in [Table 2](#pmed-1001200-t002){ref-type="table"} that, without stratification for body mass index, the relative risk estimates associated with increasing height were very slightly lower, by less than 1%, than they were with such stratification. We also assessed the effect of further adjustment for seven other potential confounding factors: ethnic group, education, age at first birth, family history of ovarian or breast cancer, age at menarche, alcohol use, and tobacco consumption. The estimates of relative risk were altered by less than 1% by additional adjustment for individual factors, and simultaneous adjustment for all seven factors did not alter the estimate.

10.1371/journal.pmed.1001200.t002

###### Relative risk of ovarian cancer in relation to height, weight, and body mass index.

![](pmed.1001200.t002){#pmed-1001200-t002-2}

  Factor                                  Cases/Controls   Relative Risk[a](#nt103){ref-type="table-fn"} (99% g-s CI)   Relative Risk[b](#nt104){ref-type="table-fn"} (99% g-s CI)
  -------------------------------------- ---------------- ------------------------------------------------------------ ------------------------------------------------------------
  **Height (cm) (mean)**                                                                                               
  \<160 (154.8)                            5,221/18,334                        1.00 (0.95--1.05)                                            1.00 (0.95--1.05)
  160-- (161.7)                            5,678/19,231                        1.09 (1.05--1.14)                                            1.10 (1.05--1.16)
  165-- (166.5)                            4,961/16,498                        1.14 (1.09--1.20)                                            1.15 (1.10--1.21)
  170+ (172.7)                             3,587/11,059                        1.24 (1.17--1.32)                                            1.27 (1.20--1.35)
  **Weight (kg) (mean)**                                                                                               
  \<60 (54.1)                              5,870/19,904                        1.00 (0.96--1.05)                                            1.00 (0.95--1.05)
  60--69 (64.2)                            6,379/22,197                        1.04 (1.00--1.08)                                            1.02 (0.97--1.06)
  70--79 (73.7)                            3,939/13,183                        1.11 (1.05--1.17)                                            1.07 (1.02--1.14)
  80+ (90.3)                               3,114/9,128                         1.24 (1.17--1.32)                                            1.18 (1.10--1.26)
  **Body mass index (kg/m^2^) (mean)**                                                                                 
  \<22.5 (20.6)                            6,299/21,009                        1.00 (0.96--1.05)                                            1.00 (0.95--1.05)
  22.5-- (23.5)                            4,024/13,554                        1.04 (0.99--1.10)                                            1.05 (1.00--1.11)
  25-- (25.9)                              4,351/14,790                        1.07 (1.02--1.12)                                            1.08 (1.02--1.13)
  27.5-- (28.4)                            1,771/5,892                         1.07 (0.99--1.16)                                            1.07 (0.99--1.17)
  30+ (33.6)                               3,043/9,435                         1.12 (1.05--1.19)                                            1.13 (1.06--1.20)

Test for trend: height, *p*\<0.001; weight, *p*\<0.001; body mass index, *p*\<0.001. Studies with hospital controls are excluded.

Relative risk stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, duration of oral contraceptive use, and ever use of menopausal hormone therapy.

Relative risk stratified as for the previous column, with additional stratification by body mass index (for height) and by height (for weight and body mass index).

The magnitude of the increase in the relative risk of ovarian cancer with increasing height did not vary substantially by age, year of birth, education, age at menarche, parity, use of oral contraceptives, menopausal status, use of menopausal hormone therapy, hysterectomy, smoking, alcohol consumption, or having first degree relatives with breast or ovarian cancer ([Figure 2](#pmed-1001200-g002){ref-type="fig"}). The trend appeared to be somewhat greater in non-white than in white women, but the difference was of borderline significance (*p* ~heterogeneity~ = 0.02), and, given the large number of comparisons made, it may well be due to chance. There was no significant heterogeneity in the relationship between height and ovarian cancer risk between prospective studies and case--control studies with population controls ([Figure 1](#pmed-1001200-g001){ref-type="fig"}; *p* ~heterogeneity~ = 0.07). Since the associations did not vary materially across the various subgroups studied and additional adjustment for other potential confounders had little effect, the overall relationship between height and the relative risk of ovarian cancer can be summarized as shown in [Figure 3](#pmed-1001200-g003){ref-type="fig"}, where the relative risks in each category of height are plotted against the mean height in that category.

![Relative risk of ovarian cancer in relation to height and BMI in various subgroups of women.\
Relative risk^1^ (RR^1^) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, body mass index, duration of oral contraceptive use, and ever use of hormone therapy (HT). Relative risk^2^ (RR^2^) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, height, duration of oral contraceptive use, and ever use of hormone therapy. ^†^ numbers do not always add to the total because of missing values; ^‡^ never-user of hormone therapy. Case--control studies with hospital controls are excluded. The dotted line represents the overall result for all women. SE, standard error.](pmed.1001200.g002){#pmed-1001200-g002}

![Relative risk of ovarian cancer by height.\
Relative risk compared to women with height \<160 cm and stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, body mass index, duration of oral contraceptive use, and ever use of hormone therapy. Relative risk estimates are plotted against the mean height in each category (\<160, 160--164, 165--169, and 170+ cm). Case--control studies with hospital controls are excluded.](pmed.1001200.g003){#pmed-1001200-g003}

Weight and Body Mass Index {#s3b}
--------------------------

The heavier and the more obese women were, the greater was their risk of ovarian cancer ([Table 2](#pmed-1001200-t002){ref-type="table"}). These results were obtained after all data were stratified by age, study, parity, menopausal status, hysterectomy, oral contraceptive use, use of hormone therapy for the menopause, and height. As expected, adjustment for height reduced the relative risks of ovarian cancer associated with increasing weight but had little effect on the relative risks associated with increasing body mass index ([Table 2](#pmed-1001200-t002){ref-type="table"}). Since the association between weight and ovarian cancer risk is dependent on height, but the association with body mass index is not, subsequent analyses focus on body mass index.

The magnitude of the increase in the relative risk of ovarian cancer with increasing body mass index did not vary significantly by women\'s age, year of birth, ethnic group, education, age at menarche, parity, use of oral contraceptives, menopausal status, hysterectomy, alcohol and tobacco use, or family history of breast or ovarian cancer ([Figure 2](#pmed-1001200-g002){ref-type="fig"}). However, use of hormone therapy for the menopause had a substantial effect on the association (*p* ~heterogeneity~\<0.001). The relative risk of ovarian cancer increased with increasing body mass index among never-users of menopausal hormone therapy, but not among ever-users (relative risk per 5 kg/m^2^ increase in body mass index of 1.10 \[95% CI, 1.07--1.13\], *p*\<0.001; and 0.95 \[95% CI, 0.92--0.99\], *p* = 0.02, respectively). Given that almost 60 subgroup-specific relative risks are shown in [Figure 2](#pmed-1001200-g002){ref-type="fig"}, the *p*-value of 0.02 for users of hormone therapy is of borderline significance, whereas the *p*-values of \<0.001 for the trend in non-users and for the difference in the trends between hormone users and non-users is unlikely to be due to chance. Such differences were observed both in prospective studies (1.08 \[95% CI, 1.04--1.12\] versus 0.94 \[95% CI, 0.90--0.99\]; *p* ~heterogeneity~\<0.001) and in case--control studies with population controls (1.13 \[95% CI, 1.08--1.18\] versus 0.99 \[95% CI, 0.91--1.08\]; *p* ~heterogeneity~ = 0.008) and did not differ when analyses were restricted to postmenopausal women.

Results in prospective studies were not significantly different when the first 4 y of follow-up were excluded. The risk estimates associated with body mass index in ever-users and never-users of hormone therapy changed by less than 2% after further adjustment for seven other potential confounding factors: ethnic group, education, age at first birth, family history of ovarian or breast cancer, age at menarche, and alcohol and tobacco consumption, and simultaneous adjustment for all these factors also affected the relative risk estimate by less than 2%. Since factors other than hormone use did not have a major effect on the relationship between ovarian cancer and body mass index, the main results are summarized in [Figure 4](#pmed-1001200-g004){ref-type="fig"} separately for never-users and ever-users of menopausal hormone therapy. The category-specific relative risks for ovarian cancer are plotted against the mean body mass index in each category.

![Relative risk of ovarian cancer by body mass index.\
Relative risk in (A) never-users of hormone therapy (HT) and (B) ever-users of hormone therapy, taking women with a body mass index of \<25 kg/m^2^ in each group as the baseline (relative risk = 1.0), and stratified by study, age at diagnosis, parity, height, and duration of oral contraceptive use. Results for never-users of hormone therapy are additionally stratified by menopausal status/hysterectomy, and results for ever-users of hormone therapy are restricted to postmenopausal women. Relative risk estimates are plotted against the mean body mass index in each category (\<25, 25--29, and 30+ kg/m^2^). Case--control studies with hospital controls are excluded.](pmed.1001200.g004){#pmed-1001200-g004}

Tumour Histology {#s3c}
----------------

Data on tumour histology was available for 17,039 (68%) women with ovarian cancer included in the main analyses. The effects of increasing height and increasing body mass index did not differ significantly between epithelial and non-epithelial tumours or between clear cell, endometrioid, mucinous, or serous histology ([Figure 5](#pmed-1001200-g005){ref-type="fig"}). However, when the data for mucinous and serous tumours were subdivided into whether they were of only borderline malignancy or were fully malignant, the trend with increasing body mass index was considerably greater for borderline serous tumours than for fully malignant serous tumours (*p* ~heterogeneity~\<0.001). Borderline malignant serous tumours make up about 5% of all the ovarian tumours included here. There were too few borderline malignant endometrioid tumours to examine separately. When analyses were restricted to never-users of menopausal hormone therapy, the associations with body mass index shown in [Figure 5](#pmed-1001200-g005){ref-type="fig"} did not change materially. The stronger association with borderline than with fully malignant serous tumours remained (relative risks per 5 kg/m^2^ increase in body mass index of 1.33 \[95% CI, 1.20--1.47\] and 1.04 \[95% CI ,1.00--1,09\], respectively, *p* ~heterogeneity~\<0.001); for the other tumour types the corresponding relative risks among never-users of hormone therapy were 1.05 (95% CI, 0.93--1.17) for clear cell, 1.10 (95% CI, 1.02--1.19) for endometrioid, and 1.14 (95% CI, 1.06--1.22) for mucinous tumours.

![Relative risk of ovarian cancer by tumour histology.\
Relative risk^1^ (RR^1^) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, body mass index, duration of oral contraceptive use, and ever use of hormone therapy. Relative risk^2^ (RR^2^) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, height, duration of oral contraceptive use, and ever use of hormone therapy. Case--control studies with hospital controls are excluded. The dotted line represents the overall result for all women with recorded histology. NOS, not otherwise specified; SE, standard error.](pmed.1001200.g005){#pmed-1001200-g005}

Public Health Implications {#s3d}
--------------------------

Based on the findings here, a 1 cm increase in height is associated with a relative risk of ovarian cancer of 1.014, and a 1 kg/m^2^ increase in body mass index with a relative risk of 1.019, in never-users of hormone therapy. In high-income countries, where average height has increased by about 1 cm per decade [@pmed.1001200-Cole1] and average body mass index by about 1 kg/m^2^ per decade [@pmed.1001200-Prospective1], the associated increase in ovarian cancer incidence would be 3% (1.019×1.014 = 1.03) per decade in never-users of hormone therapy, if all other factors relevant for the disease remained constant.

Discussion {#s4}
==========

Our collaboration has brought together and re-analysed individual data from 47 studies on ovarian cancer risk associated with adult height, weight, and body mass index, that is, most of the available epidemiological information worldwide. Collectively, the findings show a highly significant increase in the risk of ovarian cancer with increasing values for each of the anthropometric variables examined. The increase in ovarian cancer risk with increasing height and with increasing body mass index did not vary materially by women\'s age, year of birth, ethnicity, education, age at menarche, parity, family history of ovarian or breast cancer, use of oral contraceptives, menopausal status, hysterectomy, or consumption of alcohol and tobacco. However use of hormone therapy for the menopause attenuated the relationship with body mass index, since an increase in ovarian cancer risk with increasing adiposity was found only in never-users of such therapy. The trends with increasing height and body mass index were broadly similar across the common histological subtypes of ovarian cancer, except for serous tumours of borderline malignancy, which comprise 5% of the total, where the increase in risk with increasing body mass index was considerably greater than for the other tumour subtypes.

An advantage of seeking to review all epidemiological studies of ovarian cancer with relevant information on body size, published and unpublished, is that this helps avoid unduly selective emphasis on published results or just on some studies. Three eligible studies that did not contribute data to these analyses but that had published on ovarian cancer risk associated with height and/or body mass index, [@pmed.1001200-Mills1]--[@pmed.1001200-Olsen1], and some small cohorts that contributed to a fourth study [@pmed.1001200-Schouten2], together contain less than 10% as many women with ovarian cancer as are included here, and as their findings do not differ materially from those reported here, failure to include them will not have materially altered the relationships reported here. Only about half the eligible studies had published on body size and ovarian cancer risk. Few of these studies published separate results by use of hormone therapy, and so reviews based solely on published findings on the relation between body mass index and ovarian cancer risk could be misleading. The total number of studies that did not meet the eligibility criteria for this collaboration is unknown, as details of such studies have not been routinely collected over the 15 y since the collaboration began. Furthermore, despite extensive efforts to identify all eligible studies with unpublished results, it is clearly impossible to guarantee that others do not exist. It is also not possible to have completely up-to-date information from continuing prospective studies that are accumulating data beyond the time when information was contributed to this collaboration. Unpublished results from known continuing prospective studies may contain at least another 5% as many women with ovarian cancer as are included here, but there is no good reason to expect that over the next few years inclusion of additional data from such studies will materially alter the evidence that is already available.

Results from case--control studies that used hospital controls differ qualitatively and significantly from those with other study designs. It seems unlikely that these differences are due to the retrospective reporting of height and/or weight, since the results differ substantially between the retrospective studies that used hospital controls and the retrospective studies that used population controls. While other factors might also be relevant, many of the retrospective studies with hospital controls were designed to examine the effects of hormonal factors on ovarian cancer risk, and controls were often recruited from orthopaedic wards, where the most common reason for admission among middle-aged women is for hip and knee replacement surgery, and the risk of these conditions increases markedly with increasing height and increasing body mass index [@pmed.1001200-Liu1]. Using such controls to study the role of anthropometric factors in ovarian cancer would dilute, and could even reverse, any association. Since insufficient information was provided centrally on diagnoses among controls, the possibility of such biases could not be excluded, and studies with hospital controls were omitted from the main analyses. Nevertheless, to ensure that the totality of the epidemiological information is published, details of those studies are given in [Table 1](#pmed-1001200-t001){ref-type="table"} and in [Figure 1](#pmed-1001200-g001){ref-type="fig"}.

In prospective studies, height and weight were generally recorded at the time that women were recruited into the cohort, and in case--control studies, women were generally asked about their height and weight some 1--5 y before the diagnosis of ovarian cancer (for cases) and at an equivalent time for controls. In the case--control studies with population controls, the retrospective reporting of height and weight may have been influenced by the cases\' knowledge that they had ovarian cancer, but the similarity of the findings in such studies and in those with prospective recording of anthropometric factors suggests that this is probably not a serious problem here. Nonetheless, there is still likely to be some measurement error, not only in retrospective self-reported data but also with measurements made at entry into a prospective study, because women\'s weight (and, to a lesser extent, their height) may change over time. Non-differential misclassification of these variables would dilute estimates of relative risk, although the effects are likely to be comparatively small [@pmed.1001200-Cairns1].

The observed association between ovarian cancer and height did not differ significantly between prospective studies and retrospective studies with population controls, nor did it vary by the 12 personal characteristics of the women that were examined ([Figure 2](#pmed-1001200-g002){ref-type="fig"}). Variation in height reflects genetic and environmental influences, acting mostly in the first 20 or so years of life, with the role of environmental factors, including childhood nutrition and infections, believed to predominate [@pmed.1001200-Garcia1]. The observed relationship may reflect the biological influence of factors associated with adult height that are not yet well characterized or understood, such as the number of cells at risk of developing into cancer [@pmed.1001200-Albanes1] or variation in levels of circulating growth factors, such as insulin-like growth factor-1 [@pmed.1001200-Crowe1].

The association between ovarian cancer and body mass index is seen across all subgroups of women studied, except ever-users of menopausal hormone therapy. The relevance of the finding in users of menopausal hormones will be examined in a future report from this collaboration, where the direct relationship between ovarian cancer risk and use of menopausal hormone therapy will be examined, and the potential modification of any effect of hormone therapy by women\'s adiposity and other factors will be explored. Body mass index is in general a good measure of adiposity, although women with the same value for the index may vary in the relative contribution from fat and from muscle. The finding that use of hormone therapy largely eliminates the relationship between body mass index and ovarian cancer risk suggests that endogenous oestrogens may be relevant, at least among postmenopausal women: the well-characterized association between circulating oestrogen levels and increasing adiposity in postmenopausal women who do not use hormonal therapies is likely to be altered among users of these therapies [@pmed.1001200-Endogenous1]. It is unknown why the association with body mass index was greater for borderline malignant serous tumours than for other ovarian tumour types. Borderline malignant serous tumours appear to differ from fully malignant serous tumours in certain mitochondrial DNA sequences, but the relevance of these genetic differences to the observed associations with adiposity is unclear [@pmed.1001200-Aikhionbare1].

Among women in high-income countries, average height has increased by about 1 cm per decade and average body mass index has increased by about 1 kg/m^2^ per decade in the generations of women now developing ovarian cancer [@pmed.1001200-Cole1],[@pmed.1001200-Prospective1]. As an illustration of the public health consequences of such changes in height and weight, these findings suggest an associated increase in ovarian cancer incidence of 3% per decade if all other factors relevant for ovarian cancer remained constant.

Supporting Information {#s6}
======================

###### 

**PRISMA 2009 checklist.**

(DOC)

###### 

Click here for additional data file.

The following are the members of the Collaborative Group on Epidemiological Studies of Ovarian Cancer.

**Writing committee (all of whom are guarantors for these analyses):** V. Beral, C. Hermon, R. Peto, G. Reeves.

**Steering committee:** L. Brinton, P. Marchbanks, E. Negri, R. Ness, P. H. M. Peeters, M. Vessey.

**Collaborators (in alphabetical order of institution, study name, or location):** American Cancer Society, Atlanta, Georgia, US: E. E. Calle†, S. M. Gapstur, A. V. Patel; Aviano Cancer Center, Pordenone, Italy: L. Dal Maso, R. Talamini; Cancer and Radiation Epidemiology Unit, the Gertner Institute, Tel Hashomer, Israel: A. Chetrit, G. Hirsh-Yechezkel, F. Lubin, S. Sadetzki; Cancer Epidemiology Unit, Oxford, UK (Secretariat): N. Allen, V. Beral, D. Bull, K. Callaghan, B. Crossley, K. Gaitskell, A. Goodill, J. Green, C. Hermon, T. Key, K. Moser, G. Reeves; Cancer Research UK/MRC/BHF Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK: R. Collins, R. Doll†, R. Peto; Catalan Institute of Oncology, Barcelona, Spain: C. A. Gonzalez; Centers for Disease Control and Prevention, Altanta, Georgia, US: N. Lee, P. Marchbanks, H. W. Ory, H. B. Peterson, P. A. Wingo; Chiang Mai University, Chiang Mai, Thailand: N. Martin, T. Pardthaisong†, S. Silpisornkosol, C. Theetranont; Chulalongkorn University, Bangkok, Thailand: B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai; Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark: A. Tjonneland; Dartmouth Medical School, Hanover, New Hampshire, US: L. Titus-Ernstoff; Department of Epidemiology, Colorado School of Public Health, Denver, Colorado, US: T. Byers; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, US: T. Rohan; Department of Gynaecology and Obstetrics, Herlev University Hospital, Copenhagen, Denmark: B. J. Mosgaard; Department of Public Health, Oxford, UK: M. Vessey, D. Yeates; Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo, New York, US: J. L. Freudenheim; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany: J. Chang-Claude, R. Kaaks; Division of Epidemiology, University of Minnesota School of Public Health Minneapolis, Minnesota, US: K. E. Anderson, A. Folsom, K. Robien; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, US: M. A. Rossing, D. B. Thomas, N. S. Weiss; Imperial College London, London, UK: E. Riboli; Inserm U1018 and Paris South University, UMRS 1018, Institut de Cancérologie Gustave-Roussy, Villejuif, France: F. Clavel-Chapelon; Harvard Medical School, Cambridge, Massachusetts, US: D. Cramer (Brigham and Women\'s Hospital), S. E. Hankinson, S. S. Tworoger (Channing Laboratory) for the Nurses\' Health Study; International Agency for Research in Cancer, Lyon, France: S. Franceschi; Istituto di Ricerche Farmacologiche Mario Negri, University of Milan, Milan, Italy: C. La Vecchia, E. Negri; Karolinska Institutet, Stockholm, Sweden: C. Magnusson, T. Riman, E. Weiderpass, A. Wolk; Maastricht University, Maastricht, Netherlands: L. J. Schouten, P. A. van den Brandt; Mahidol University, Bangkok, Thailand: N. Chantarakul, S. Koetsawang, D. Rachawat; Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute, Florence, Italy: D. Palli; National Cancer Institute, Bethesda, Maryland, US: A. Black, A. Berrington de Gonzalez, L. A. Brinton, D. M. Freedman, P. Hartge, A. W. Hsing, J. V. Lacey, Jr., R. N. Hoover, C. Schairer; Norwegian Institute of Public Health, Oslo, Norway: S. Graff-Iversen, R. Selmer; Queensland Institute of Medical Research and University of Queensland: C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb; Roswell Park Cancer Institute, Buffalo, New York, US: S. E. McCann; Royal College of General Practitioners\' Oral Contraception Study, London, UK: P. Hannaford, C. Kay; School of Public Health, Curtin University of Technology, Perth, Australia: C. W. Binns, A. H. Lee, M. Zhang; School of Public Health, University of Texas, Houston, Texas, US: R. B. Ness; School of Public Health and Health Sciences, University of Massachusetts, Boston, Massachusetts, US: P. Nasca; Slone Epidemiology Center, Boston University, Boston, Massachusetts, US: P. F. Coogan, J. R. Palmer, L. Rosenberg; Stanford University, Stanford, California, US: J. Kelsey, R. Paffenbarger†; A. Whittemore; University of Athens Medical School, Athens, Greece: K. Katsouyanni, A. Trichopoulou, D. Trichopoulos, A. Tzonou; University of Chile, Santiago, Chile: A. Dabancens, L. Martinez, R. Molina, O. Salas; University of Hawaii, Honolulu, Hawaii, US: M. T. Goodman, G. Lurie, M. E. Carney, L. R. Wilkens; University Hospital, Lund, Sweden: L. Hartman, J. Manjer, H. Olsson; University of Pennsylvania, Philadelphia, Pennsylvania, US: J. A. Grisso, M. Morgan, J. E. Wheeler; University Medical Center Utrecht, Utrecht, Netherlands: P. H. M. Peeters; University of Southern California, Los Angeles, California, US: J. Casagrande, M. C. Pike, R. K. Ross†, A. H. Wu; University of Toronto, Toronto, Ontario, Canada: A. B. Miller; University of Tromso, Tromso, Norway: M. Kumle, E. Lund; George Washington University, Washington, District of Columbia, US: L. McGowan; Vanderbilt University, Nashville, Tennessee, US: X. O. Shu, W. Zheng; World Health Organization, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland: T. M. M. Farley, S. Holck, O. Meirik; Yale School of Public Health, Yale, Connecticut, US: H. A. Risch. † Deceased.

The authors have declared that no competing interests exist.

Funding for this collaborative reanalyis of original data was provided by Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

CI

:   confidence interval

g-s CI

:   group-specific confidence interval

[^1]: This manuscript is one of a series of papers by a group author, 'The Collaborative Group on Epidemiological Studies of Ovarian Cancer'. Individual data from 47 separate studies have been submitted centrally by all collaborators listed in the Acknowledgments section. Each collaborator was responsible for the design of one or more of the 47 contributing epidemiological studies. All collaborators have seen this manuscript and a previous version, and their comments are incorporated here. Analyzed the data: VB CH RP GR. Wrote the first draft of the manuscript: VB CH RP GR. Contributed to the writing of the manuscript: Collaborators. [ICMJE](http://www.icmje.org/) criteria for authorship read and met: VB CH RP GR. Agree with manuscript results and conclusions: Collaborators.
